Healthplus Technologies

Name: Healthplus Technologies
Brand: Healthplus.ai

Healthplus Technologies develops PERISCOPE®, a clinical decision support system that predicts 7-day and 30-day post-operative infection risk from EHR data, surfaces contributing factors for explainability, and delivers risk scores within EHR workflows to inform perioperative clinical decision-making.

Est 2017|15 Ref Customers

LinkedIn 3K|Website|FTEs 17

Published Oct 12, 2026

01Common complaints

Company sizes or stages where this product is overkill or insufficient
- Small hospitals or clinics without dedicated integration and governance teams may find the solution disproportionate to their needs.
Industries or use cases where competitors are more appropriate
- ICU sepsis prediction: purpose-built tools for sepsis or EHR-native sepsis tooling may be more directly aligned to that domain.
- Broad hospital analytics: Epic/Cerner platforms or enterprise analytics suites may provide broader coverage beyond a single complication focus.
Technical requirements that this product cannot meet
- If an organization requires a turnkey solution with no EHR integration work, an EHR-integrated SaMD will likely not meet that need.
Budget constraints that make alternatives more appropriate
- If budget cannot support integration, monitoring, and recurring license costs, simpler surveillance tools or in-house scoring may be more viable.
Specific workflows or integrations where the product falls short
- If EHR data capture for perioperative events is inconsistent, predictions relying on that data may be unreliable.
Red flags in the buying process
- If the vendor cannot provide:
  - model performance reports tailored to the hospital
  - clear data-flow diagrams and security documentation
  - an update and drift monitoring plan
  - MDR documentation appropriate for the jurisdiction
Current limitations acknowledged by the vendor
- The PERISCOPE IFU indicates a minimum performance threshold; if minimum performance cannot be met for a given deployment, the system will show no predictions (a safety measure described by the vendor).
Features on the roadmap (not yet available) - note estimated dates if available
- The vendor indicates intent to pursue FDA clearance and deepen integrations with Epic, Cerner, and ChipSoft; no public dates for FDA clearance are provided.
Scale limitations (at what volume/size does it break down?)
- Not publicly documented.
Security or compliance gaps
- While ISO 27001 certification is stated, SOC 2 and HIPAA-specific disclosures were not found publicly.
Technical debt or architectural limitations mentioned in reviews
- Not available in accessible sources.
API limitations or integration constraints
- Not publicly detailed; procurement should include a review of the implementation guide and integration requirements.

- Company sizes or stages where this product is overkill or insufficient - Small hospitals or clinics without dedicated integration and governance teams may find the solution disproportionate to their needs. - Industries or use cases where competitors are more appropriate - ICU sepsis prediction: purpose-built tools for sepsis or EHR-native sepsis tooling may be more directly aligned to that domain. - Broad hospital analytics: Epic/Cerner platforms or enterprise analytics suites may provide broader coverage beyond a single complication focus. - Technical requirements that this product cannot meet - If an organization requires a turnkey solution with no EHR integration work, an EHR-integrated SaMD will likely not meet that need. - Budget constraints that make alternatives more appropriate - If budget cannot support integration, monitoring, and recurring license costs, simpler surveillance tools or in-house scoring may be more viable. - Specific workflows or integrations where the product falls short - If EHR data capture for perioperative events is inconsistent, predictions relying on that data may be unreliable. - Red flags in the buying process - If the vendor cannot provide: - model performance reports tailored to the hospital - clear data-flow diagrams and security documentation - an update and drift monitoring plan - MDR documentation appropriate for the jurisdiction - Current limitations acknowledged by the vendor - The PERISCOPE IFU indicates a minimum performance threshold; if minimum performance cannot be met for a given deployment, the system will show no predictions (a safety measure described by the vendor). - Features on the roadmap (not yet available) - note estimated dates if available - The vendor indicates intent to pursue FDA clearance and deepen integrations with Epic, Cerner, and ChipSoft; no public dates for FDA clearance are provided. - Scale limitations (at what volume/size does it break down?) - Not publicly documented. - Security or compliance gaps - While ISO 27001 certification is stated, SOC 2 and HIPAA-specific disclosures were not found publicly. - Technical debt or architectural limitations mentioned in reviews - Not available in accessible sources. - API limitations or integration constraints - Not publicly detailed; procurement should include a review of the implementation guide and integration requirements.

Why some customers left for competitors (churn reasons)

Not publicly documented.

02Why they buy

Competitive advantages validated by customer feedback (not just vendor claims)
- Customer-validated advantages were not found in accessible review platforms; buyers should request references and validation materials.
Unique features and capabilities competitors lack
- The vendor claims that there is no comparable product worldwide; this is a vendor claim and should be validated against other infection surveillance and perioperative analytics vendors.
- More verifiable differentiators:
  - CE marking under EU MDR for the stated SaMD indication (as presented by the vendor)
  - Published validation research items linked on the vendor resources page (supporting model development/validation)
  - ISO 27001 certification claim in the privacy statement
Differentiation from competitors based on reviews
- Not available in accessible third-party review corpora.
Value propositions with evidence from case studies
- Peer-reviewed research listings exist, but operational ROI outcomes and multi-site deployment effectiveness are less clearly documented publicly.
Areas where competitors clearly have advantages (be balanced)
- Epic/Cerner ecosystems: existing relationships, broader workflows, and fewer additional third-party vendors
- Niche vendors may provide deeper modules for infection surveillance reporting, antimicrobial stewardship, or multi-condition deterioration prediction

- Competitive advantages validated by customer feedback (not just vendor claims) - Customer-validated advantages were not found in accessible review platforms; buyers should request references and validation materials. - Unique features and capabilities competitors lack - The vendor claims that there is no comparable product worldwide; this is a vendor claim and should be validated against other infection surveillance and perioperative analytics vendors. - More verifiable differentiators: - CE marking under EU MDR for the stated SaMD indication (as presented by the vendor) - Published validation research items linked on the vendor resources page (supporting model development/validation) - ISO 27001 certification claim in the privacy statement - Differentiation from competitors based on reviews - Not available in accessible third-party review corpora. - Value propositions with evidence from case studies - Peer-reviewed research listings exist, but operational ROI outcomes and multi-site deployment effectiveness are less clearly documented publicly. - Areas where competitors clearly have advantages (be balanced) - Epic/Cerner ecosystems: existing relationships, broader workflows, and fewer additional third-party vendors - Niche vendors may provide deeper modules for infection surveillance reporting, antimicrobial stewardship, or multi-condition deterioration prediction

Why customers chose this product over alternatives

Likely drivers (vendor claims, not independently verified):
- CE marking under EU MDR for this SaMD indication
- EHR-integrated workflow approach
- focus on post-operative infection risk (a specific clinical problem)

03Field reports

Availability caveat (important)

For this vendor/product, traditional review-platform coverage appears limited or difficult to verify:
- Gartner Peer Insights: No clearly accessible listing for Healthplus.ai / PERISCOPE was found.
- TrustRadius: No Healthplus.ai product page with reviews found via accessible search.
- G2: A G2 page exists referencing "healthplus.ai" alternatives, but it appears category-mismatched and does not provide credible healthcare-specific peer review content.

- For this vendor/product, traditional review-platform coverage appears limited or difficult to verify: - Gartner Peer Insights: No clearly accessible listing for Healthplus.ai / PERISCOPE was found. - TrustRadius: No Healthplus.ai product page with reviews found via accessible search. - G2: A G2 page exists referencing "healthplus.ai" alternatives, but it appears category-mismatched and does not provide credible healthcare-specific peer review content.

Direct quotes from mainstream review platforms and community forums

No reliable, direct user-review quotes specifically about Healthplus.ai PERISCOPE were found on Gartner Peer Insights, G2, or TrustRadius in accessible sources.
Broader community discussions about healthcare AI include recurring themes of skepticism about generic AI advice and the need for rigorous validation. Example sentiment seen in non-product-specific threads: "The prototype-to-production gap in healthcare AI is often about workflow, not the model."

Balance and recommendations

Due to the limited availability of product-specific third-party reviews, a precise distribution of high- vs low-end ratings for Healthplus.ai PERISCOPE cannot be credibly provided.
Recommendation: treat the absence of broad third-party reviews as a risk factor (limited public peer validation). Buyers should request:
- reference calls (clinicians and IT/infosec contacts)
- local validation results and performance reports
- documented performance, calibration, and subgroup analyses

- Due to the limited availability of product-specific third-party reviews, a precise distribution of high- vs low-end ratings for Healthplus.ai PERISCOPE cannot be credibly provided. - Recommendation: treat the absence of broad third-party reviews as a risk factor (limited public peer validation). Buyers should request: - reference calls (clinicians and IT/infosec contacts) - local validation results and performance reports - documented performance, calibration, and subgroup analyses

Common criticisms and complaints (support issues, bugs, missing features)

Product-specific complaints were not found via accessible public review sources.
Category-level likely complaints (based on comparable EHR-integrated predictive tools):
- alert fatigue and workflow burden
- integration friction (EHR upgrade breakage, interface variability)
- limited transparency of model performance and drift monitoring
- challenges proving ROI outside pilot settings

Specific outcomes customers achieved (with metrics when available)

Vendor messaging and investor materials highlight outcomes, but prominent quantitative claims accessible publicly were not tied to independently audited, multi-site real-world evaluations.
Treat outcome metrics as vendor-published unless supported by peer-reviewed, independent deployment evaluations.

Deal-breakers and reasons customers didn't purchase

Not directly available, but common deal-breakers for hospital SaMD/CDSS purchases include:
- inability to pass security review
- unclear liability and governance
- insufficient local validation
- EHR integration constraints
- unclear pricing and ROI

Case Studies

Detailed customer success stories with metrics
- The vendor provides an evidence/resources section listing peer‑reviewed research and news; however, public‑facing hospital‑by‑hospital case studies with audited outcomes were limited in accessible materials.
- A vendor news post (March 28, 2024) states CE certification under MDR and references prevalence and cost‑impact claims; these broad claims may not generalize and should be validated locally.
Specific results and quantified business impact
- The vendor references clinical validation and peer‑reviewed studies (for model development/validation), but published validation alone does not prove net clinical benefit post‑implementation.
Implementation details and time to value
- Official vendor guidance: a multi‑week implementation period is typical.
- The IFU emphasizes verifying the availability of a model performance report before clinical use.
Challenges faced during adoption and how they were resolved
- Not described in detail in accessible public case studies.
CRITICAL: Note when metrics are vendor‑published without independent verification
- Several vendor‑published claims, including comparative product uniqueness and generalized cost‑savings claims, should be validated independently.
Note methodology gaps
- Buyers should ask the vendor for:
  - information on performance variation by hospital population and surgical specialty
  - details on calibration and drift monitoring approaches
  - evidence of whether the tool changes clinician behavior in ways that affect labels (measurement bias)

- Detailed customer success stories with metrics - The vendor provides an evidence/resources section listing peer‑reviewed research and news; however, public‑facing hospital‑by‑hospital case studies with audited outcomes were limited in accessible materials. - A vendor news post (March 28, 2024) states CE certification under MDR and references prevalence and cost‑impact claims; these broad claims may not generalize and should be validated locally. - Specific results and quantified business impact - The vendor references clinical validation and peer‑reviewed studies (for model development/validation), but published validation alone does not prove net clinical benefit post‑implementation. - Implementation details and time to value - Official vendor guidance: a multi‑week implementation period is typical. - The IFU emphasizes verifying the availability of a model performance report before clinical use. - Challenges faced during adoption and how they were resolved - Not described in detail in accessible public case studies. - CRITICAL: Note when metrics are vendor‑published without independent verification - Several vendor‑published claims, including comparative product uniqueness and generalized cost‑savings claims, should be validated independently. - Note methodology gaps - Buyers should ask the vendor for: - information on performance variation by hospital population and surgical specialty - details on calibration and drift monitoring approaches - evidence of whether the tool changes clinician behavior in ways that affect labels (measurement bias)

04Best fit

Ideal Customer Profile

Company sizes
- Best fit is mid-to-large hospitals and health systems with established perioperative pathways and infection control programs, and with EHR integration capacity.
Industries and verticals where adoption is strongest (with customer examples)
- Acute-care hospitals and surgical centers within hospital systems. The vendor indicates deployments across the Netherlands, Belgium, Denmark, and the UK.
Roles and personas: decision makers AND end users
- Decision makers: CMIO/CCIO, CIO/IT leadership, Chief Quality Officer/Patient Safety, surgical service line leadership, infection prevention leadership, procurement, legal/compliance
- End users: surgeons, perioperative nurses, infection prevention teams, quality improvement staff
Pain points and challenges the product addresses
- Earlier detection of post-operative infection risk, reducing delayed diagnosis and complications, and providing risk information within EHR workflows
Qualification criteria: what makes a GREAT fit
- Strong EHR data quality and structured perioperative documentation; willingness to operationalize risk predictions into clinical pathways; capability to monitor outcomes and iterate on workflow
Deal disqualifiers: what makes a POOR fit
- Low surgical volume, fragmented EHR environments or limited integration resources, inability to support SaMD governance and monitoring, or requirement for publicly documented HIPAA/HITRUST attestations (for U.S.)

- Company sizes - Best fit is mid-to-large hospitals and health systems with established perioperative pathways and infection control programs, and with EHR integration capacity. - Industries and verticals where adoption is strongest (with customer examples) - Acute-care hospitals and surgical centers within hospital systems. The vendor indicates deployments across the Netherlands, Belgium, Denmark, and the UK. - Roles and personas: decision makers AND end users - Decision makers: CMIO/CCIO, CIO/IT leadership, Chief Quality Officer/Patient Safety, surgical service line leadership, infection prevention leadership, procurement, legal/compliance - End users: surgeons, perioperative nurses, infection prevention teams, quality improvement staff - Pain points and challenges the product addresses - Earlier detection of post-operative infection risk, reducing delayed diagnosis and complications, and providing risk information within EHR workflows - Qualification criteria: what makes a GREAT fit - Strong EHR data quality and structured perioperative documentation; willingness to operationalize risk predictions into clinical pathways; capability to monitor outcomes and iterate on workflow - Deal disqualifiers: what makes a POOR fit - Low surgical volume, fragmented EHR environments or limited integration resources, inability to support SaMD governance and monitoring, or requirement for publicly documented HIPAA/HITRUST attestations (for U.S.)

05The pitch

What the product does (core value proposition in objective terms)

Healthplus.ai (Healthplus.ai-Operations B.V.) develops PERISCOPE®, a clinical decision support product that predicts post-operative infection risk using data from a hospital’s EHR, intended to help surgical teams identify patients at higher risk earlier and support clinical decision-making.
Product positioning notes:
- EHR-native workflow (integrates with existing EHR processes; vendor states no separate logins and limited additional data entry requirements)
- Risk prediction horizons spanning short-term and medium-term post-surgery periods (days to weeks) as described on the vendor site
- Explainability features that indicate contributing factors, and an explicit framing that the tool is clinical decision support rather than a replacement for clinician judgment

- Healthplus.ai (Healthplus.ai-Operations B.V.) develops PERISCOPE®, a clinical decision support product that predicts post-operative infection risk using data from a hospital’s EHR, intended to help surgical teams identify patients at higher risk earlier and support clinical decision-making. - Product positioning notes: - EHR-native workflow (integrates with existing EHR processes; vendor states no separate logins and limited additional data entry requirements) - Risk prediction horizons spanning short-term and medium-term post-surgery periods (days to weeks) as described on the vendor site - Explainability features that indicate contributing factors, and an explicit framing that the tool is clinical decision support rather than a replacement for clinician judgment

Target market and market positioning

Primary buyer: hospitals and health systems (perioperative departments, surgical services, infection prevention, quality/safety leadership)
Implementation requires involvement from enterprise IT and clinical governance due to:
- EHR integration requirements
- Medical device regulatory obligations (EU MDR)
- Data protection and security review processes
Market positioning is focused on predictive perioperative risk / post-op infection prediction rather than consumer-facing AI health tools.

- Primary buyer: hospitals and health systems (perioperative departments, surgical services, infection prevention, quality/safety leadership) - Implementation requires involvement from enterprise IT and clinical governance due to: - EHR integration requirements - Medical device regulatory obligations (EU MDR) - Data protection and security review processes - Market positioning is focused on predictive perioperative risk / post-op infection prediction rather than consumer-facing AI health tools.

Get a comprehensive analysis of Healthplus Technologies including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →